跳至主要内容
临床试验/EUCTR2007-003233-16-ES
EUCTR2007-003233-16-ES进行中(未招募)不适用

A multicenter, double-blind, randomized, placebo-controlled extension study assessing the efficacy and long-term safety of a 2mg dose of TH9507, a growth hormone releasing factor analog, in HIV subjects with excess abdominal fat accumulation.Estudio de extesión, multicéntrico, doble ciego, aleatorizado, controlado con placebo para evaluar la eficacia y seguridad a largo plazo de una dosis de 2 mg de TH9507, un análogo del factor liberador de la hormona de crecimiento, en sujetos con VIH con acumulación excesiva de grasa abdominal.

Theratechnologies Inc.0 个研究点目标入组 300 人开始时间: 2007年10月22日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Subjects who have completed the 26 weeks treatment period of the TH9507-CTR-1011 study.
  • 2. Signed informed consent before any trial-related activities.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Fasting blood glucose >8.33 mmol/L (150 mg/dL) at the end of the TH9507-CTR-1011 study.

研究者

相似试验

进行中(未招募)
1 期
A research study to study the effects of a new oral drug called lucerastat in adults with Fabry diseaseFabry diseaseMedDRA version: 20.0Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2017-003369-85-NLIdorsia Pharmaceuticals Ltd99
已完成
3 期
A multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, Phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertensiohypertension in lung arteries10037454Pulmonary hypertension
NL-OMON33990Actelion Pharmaceuticals Ltd.24
进行中(未招募)
不适用
A multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, Phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension - SERAPHITo assess the effects of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertensionMedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertension
EUCTR2007-002440-14-DEActelion Pharmaceuticals Ltd.700
进行中(未招募)
不适用
A multicenter, double-blind, randomized, placebo-controlled, two-arm parallel-group study of BGG492 as monotherapy in individuals with refractory partial seizures undergoing inpatient evaluation for epilepsy surgeryMedDRA version: 9.1Level: LLTClassification code 10061334Term: Partial seizuresEpilepsy
EUCTR2008-005065-64-DEovartis Pharma Services AG
进行中(未招募)
1 期
A research study to study the effects of a new oral drug called lucerastat in adults with Fabry diseaseFabry diseaseMedDRA version: 20.0Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2017-003369-85-GBIdorsia Pharmaceuticals Ltd99